Targeting the UPS to Treat NDDs Flashcards
Areas to target the UPS for treatment of NDDs
- Stimulate Ubiquitylation
- inhibit DUB
- Increase proteasome proteolytic capacity
PROTACS
AKA PROteolysis-Targeting Chimeras
– heterobifunctional molecules with a Protein binding site, E3 ligase binding site and flexible chemical linker
Structure of PROTACS
Protein of interest (POI)-binding site and E3 ligase binding site bound together through flexible chemical linker
Binding to Protacs
POI binding site binds target protein –> Binding induces induce artificial ubiquitination, leading to and degradation of the protein by the proteasome
First vs. second gen PROTACs
- First generation Protacs too bulky to get into cells (therefore not super successful)
- Second generation of Protacs: non-peptide, small molecules membrane-permeable
PROTACS in HD
- Under investigation in cellular models of HD (patient fibroblasts)
- Benefit: tissue specificity by developing molecules that recruit E3 ligases only expressed in a certain tissue
PROTACS in AD
Patent for PROTAC of tau binding moieties linked to E3 ligase binding moiety (thalidomide)
– can induce ubiquitination of tau protein and promote its degradation in cells
Targeting DUBs
Targeting DUBs is the easiest way to increase UPS activity
– DUBs are the most druggable enzymes within UPS
DUB function
DUBs acting upstream of the proteasome may act as a “rescue crew”
– they salvage specific substrates by deubiquitination before they are engaged in degradation
DUB inhibition
DUB inhibitors may accelerate the turnover of the specific substrate for proteasome-mediated degradation
Inhibition of UPS14
Inhibiting the catalytic activity of USP14 may have therapeutic benefits in NDDs
as it increases protosomal degradation by preventing premature deubiquitination
USP24 function
USP14 is responsible for trimming Ub chains on substrates destined for degradation and thus recycling mono-Ub
USP14 binding area
USP14 and UCHL5 associate reversibly to the 19S lid
Premature USP14 activation
Premature deubiquitination by USP14 can
prevent protein degradation
USP14 Inhibitors in NDDs
- USP14 inhibitors are under development for the clearance of aggregation-prone proteins
- Extent of USP14 contribution to the clearance of proteins involved in neurodegeneration in vivo remains controversial
– Inactivation or depletion of USP14 may not be beneficial in all NDDs
Drawbacks of USP14 inhibitors
Potential drawbacks because USP14 loss causes severe morbidity and postnatal lethality in mice
IU1
- USP14 inhibitor
- small molecule with remarkable specificity
against USP14
IU1 was discovered by
– identified by high-throughput screening
IU1 function
Enhances clearance of disease-linked proteins in cultured cells in a proteasome- dependent manner:
– Tau, ATXN3
T/F: IU1 has been shown to prevent ND in vivo
FALSE
It remains to be determined if IU1 can prevent
neurodegeneration in vivo
Acute effects of USP inactivation
Acute inactivation of USP14 could
increase degradation of some disease proteins without perturbing Ub homeostasis
Chronic effects of USP inactviation
Chronic inactivation of USP14 could cause an overall disturbance in mono-Ub availability that leads to compensatory mechanisms of protein turnover
lack of mono-Ub –> can’t tag for degradation –> new mechanism
Nrf1 and Nrf2
- are transcription factors for
proteasome genes - Nrf1 and Nrf2 are also substrates of proteasomal degradation
Nrf1 activity
Nrf1 only becomes active in the nucleus when increased UPS function is required
when only need low UPS –> Nrf1 isn’t active